guest ::
| Home > Publications database > A Glyoxalase-1 Knockdown Does Not Have Major Short Term Effects on Energy Expenditure and Atherosclerosis in Mice. > print |
| Home > Publications database > A Glyoxalase-1 Knockdown Does Not Have Major Short Term Effects on Energy Expenditure and Atherosclerosis in Mice. > print |
| 001 | 130974 | ||
| 005 | 20240228143505.0 | ||
| 024 | 7 | _ | |a 10.1155/2016/2981639 |2 doi |
| 024 | 7 | _ | |a pmid:26788517 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC4693023 |2 pmc |
| 024 | 7 | _ | |a 1543-8600 |2 ISSN |
| 024 | 7 | _ | |a 1543-8619 |2 ISSN |
| 024 | 7 | _ | |a 1687-5214 |2 ISSN |
| 024 | 7 | _ | |a 1687-5303 |2 ISSN |
| 024 | 7 | _ | |a 2314-6745 |2 ISSN |
| 024 | 7 | _ | |a 2314-6753 |2 ISSN |
| 024 | 7 | _ | |a altmetric:5021793 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2017-06050 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Wortmann, Markus |b 0 |
| 245 | _ | _ | |a A Glyoxalase-1 Knockdown Does Not Have Major Short Term Effects on Energy Expenditure and Atherosclerosis in Mice. |
| 260 | _ | _ | |a New York, NY [u.a.] |c 2016 |b Hindawi |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1521190815_1657 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Objective. Glyoxalase-1 is an enzyme detoxifying methylglyoxal (MG). MG is a potent precursor of advanced glycation endproducts which are regarded to be a key player in micro- and macrovascular damage. Yet, the role of Glo1 in atherosclerosis remains unclear. In this study, the effect of Glo1 on mouse metabolism and atherosclerosis is evaluated. Methods. Glo1 knockdown mice were fed a high fat or a standard diet for 10 weeks. Body weight and composition were investigated by Echo MRI. The PhenoMaster system was used to measure the energy expenditure. To evaluate the impact of Glo1 on atherosclerosis, Glo1(KD) mice were crossed with ApoE-knockout mice and fed a high fat diet for 14 weeks. Results. Glo1 activity was significantly reduced in heart, liver, and kidney lysates derived from Glo1(KD) mice. Yet, there was no increase in methylglyoxal-derived AGEs in all organs analyzed. The Glo1 knockdown did not affect body weight or body composition. Metabolic studies via indirect calorimetry did not show significant effects on energy expenditure. Glo1(KD) mice crossed to ApoE(-/-) mice did not show enhanced formation of atherosclerosis. Conclusion. A Glo1 knockdown does not have major short term effects on the energy expenditure or the formation of atherosclerotic plaques. |
| 536 | _ | _ | |a 311 - Signalling pathways, cell and tumor biology (POF3-311) |0 G:(DE-HGF)POF3-311 |c POF3-311 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 650 | _ | 7 | |a Apolipoproteins E |2 NLM Chemicals |
| 650 | _ | 7 | |a Pyruvaldehyde |0 722KLD7415 |2 NLM Chemicals |
| 650 | _ | 7 | |a Lactoylglutathione Lyase |0 EC 4.4.1.5 |2 NLM Chemicals |
| 700 | 1 | _ | |a Hakimi, Maani |b 1 |
| 700 | 1 | _ | |a Fleming, Thomas |b 2 |
| 700 | 1 | _ | |a Peters, Andreas S |b 3 |
| 700 | 1 | _ | |a Sijmonsma, Tjeerd |0 P:(DE-He78)2907fb4a25af2d45366a9dbc819ca116 |b 4 |u dkfz |
| 700 | 1 | _ | |a Herzig, Stephan |0 P:(DE-He78)e527f794b23172e769c8904180546f57 |b 5 |u dkfz |
| 700 | 1 | _ | |a Nawroth, Peter P |b 6 |
| 700 | 1 | _ | |a Böckler, Dittmar |b 7 |
| 700 | 1 | _ | |a Dihlmann, Susanne |b 8 |
| 773 | _ | _ | |a 10.1155/2016/2981639 |g Vol. 2016, p. 1 - 8 |0 PERI:(DE-600)2711897-6 |p 1 - 8 |t Journal of diabetes research |v 2016 |y 2016 |x 2314-6753 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:130974 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)2907fb4a25af2d45366a9dbc819ca116 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)e527f794b23172e769c8904180546f57 |
| 913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-311 |2 G:(DE-HGF)POF3-300 |v Signalling pathways, cell and tumor biology |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
| 914 | 1 | _ | |y 2016 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J DIABETES RES : 2015 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |
| 915 | _ | _ | |a Creative Commons Attribution CC BY (No Version) |0 LIC:(DE-HGF)CCBYNV |2 V:(DE-HGF) |b DOAJ |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |
| 920 | 1 | _ | |0 I:(DE-He78)A170-20160331 |k A170 |l Molekulare Stoffwechselkontrolle |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)A170-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|